DalsnaFinance

Innate Pharma $IPHA

Health Care

France
Create a scorecard
$1.58
+0.02 (+1.28%)
As of Oct 5, 2026, 5:11 PM EDT
Price history
Loading chart…

Innate Pharma (IPHA) is trading up at $1.58 (+1.28%), as of the latest quote. It operates in the Health Care sector.

IPO: October 17, 2019 · $5.50 offering · NASDAQ · View IPO details →

Innate Pharma revenue & net income history (FY2017–FY2025)

RevenueNet income
€94.0M€15.0M−€64.0MFY2017 revenue: €44.0MFY2017 net income: −€48.4M'17FY2018 revenue: €94.0MFY2018 net income: €3.05M'18FY2019 revenue: €85.4MFY2019 net income: −€20.8M'19FY2020 revenue: €69.8MFY2020 net income: −€64.0M'20FY2021 revenue: €24.7MFY2021 net income: −€52.8M'21FY2022 revenue: €57.7MFY2022 net income: −€58.1M'22FY2023 revenue: €61.6MFY2023 net income: −€7.57M'23FY2024 revenue: €20.1MFY2024 net income: −€49.5M'24FY2025 revenue: €9.01MFY2025 net income: −€49.2M'25
Innate Pharma annual financial statements
FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue€44.0M€94.0M€85.4M€69.8M€24.7M€57.7M€61.6M€20.1M€9.01M
Growth (year over year)—+113.4%−9.1%−18.3%−64.6%+133.5%+6.9%−67.4%−55.2%
Operating income−€40.0M€5.15M€1.57M€1.08M−€47.8M−€57.4M−€12.7M−€51.6M−€54.0M
Operating margin−90.8%5.5%1.8%1.5%−193.6%−99.6%−20.6%−256.3%−599.8%
Net income−€48.4M€3.05M−€20.8M−€64.0M−€52.8M−€58.1M−€7.57M−€49.5M−€49.2M
Net margin−109.9%3.2%−24.3%−91.7%−213.8%−100.7%−12.3%−245.9%−546.1%
EPS (diluted)−€0.89€0.05−€0.31−€0.81−€0.66−€0.73−€0.09−€0.61−€0.55
Balance sheet
Cash and equivalents€99.4M€152.3M€202.9M€136.8M€103.8M€84.2M€70.6M€66.4M€28.1M
Total assets€255.0M€451.2M€401.4M€307.4M€267.5M€199.3M€175.2M€111.1M€62.7M
Total liabilities€155.6M€284.1M€183.9M€151.4M€160.1M€145.1M€123.3M€102.2M€84.4M
Shareholders' equity€99.4M€167.1M€217.4M€156.0M€107.4M€54.2M€51.9M€8.83M−€21.7M
Cash flow
Operating cash flow−€48.1M−€32.5M€34.9M−€51.8M−€58.5M−€19.2M−€32.6M−€6.90M−€52.8M
Capital expenditure€2.96M€873.0K€1.27M€907.0K€929.0K€535.0K€351.0K€391.0K€140.0K
Free cash flow−€51.0M−€33.4M€33.7M−€52.7M−€59.4M−€19.7M−€32.9M−€7.29M−€52.9M

From Innate Pharma's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Amounts are in Euro (EUR), as reported, not converted to dollars. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →

About Innate Pharma

Headquarters
Marseille, France From SEC filings, Oct 2026

Recent News (1)

More Health Care stocks

Browse all companies →